February 8, 2013
Otsuka Pharmaceutical Co., Ltd.
7.5mg Tablets Additionally Approved - Samsca®, Vasopressin V2 Receptor Antagonist
Tokyo, Japan, February 8, 2013 - Otsuka Pharmaceutical Co., Ltd. today announced that Samsca® (tolvaptan), vasopressin V2 receptor antagonist indicated for the treatment of volume overload in patients with heart failure, was granted additional approval of tablets in 7.5mg dosage on February 4, 2013.
Information in this news release was current as of the original release date.